Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2Sarcoma 1Breast 1

Conditions

Ovarian Neoplasms 45Breast Neoplasms 39Triple Negative Breast Neoplasms 19Prostatic Neoplasms 17Neoplasms 13Fallopian Tube Neoplasms 13Endometrial Neoplasms 12Recurrence 8Pancreatic Neoplasms 8Neoplasm Metastasis 8Squamous Cell Carcinoma of Head and Neck 7Small Cell Lung Carcinoma 7Lung Neoplasms 6Carcinoma, Ovarian Epithelial 6Glioma 5Glioblastoma 5Carcinoma, Renal Cell 5Uterine Cervical Neoplasms 4Sarcoma 4Carcinoma, Squamous Cell 4Carcinoma, Non-Small-Cell Lung 4Advanced Breast Cancer 4Stomach Neoplasms 3Solid Tumor 3Melanoma 3Head and Neck Neoplasms 3Fanconi Anemia, Complementation Group D1 3Uveal Melanoma 2Uterine Neoplasms 2Urinary Bladder Neoplasms 2

Interventions

Radiosurgery 114Temozolomide 104Bevacizumab 71Radiotherapy 67Magnetic Resonance Spectroscopy 67Carboplatin 29pembrolizumab 28Irinotecan 26Surgical Procedures, Operative 25Radiation 23Nivolumab 23Etoposide 22Magnetic Resonance Imaging 21Ipilimumab 21Erlotinib Hydrochloride 21Cyclophosphamide 21Surveys and Questionnaires 19Aminolevulinic Acid 18Specimen Handling 16Pemetrexed 16Mental Status and Dementia Tests 16Cisplatin 16Carmustine 15Topotecan 14Trastuzumab 13Saline Solution 12Neuropsychological Tests 12Gefitinib 11Filgrastim 11Drug Therapy 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Brain Neoplasms × olaparib × Clear all
NCT04711824 2025-12-23

SOLARA

Hoosier Cancer Research Network

Phase 1/2 Recruiting
41 enrolled
BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT01390571 2018-02-05

Olaparib and Temozolomide in Treating Patients With Relapsed Glioblastoma

Cancer Research UK

Phase 1 Completed
34 enrolled
CNSSarcoma

Brain Neoplasms, Glioblastoma, Central Nervous System Neoplasms, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡